Señales en vivo de CADL | Maximiza tus Ganancias con Getagraph.com

COMPRAR 2788 min ago

@ $11.45

Emitido: 17 may 2024 @ 11:14

Retorno: 0.42%

Señal anterior: may 17 - 09:30

Señal anterior: Vender

Retorno: -12.98 %

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 16:00):

Stats
Volumen de hoy	833 352
Volumen promedio	5.49M
Capitalización de mercado	342.06M
EPS	$0 ( 2024-05-09 )
Próxima fecha de ganancias	( $0 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.78
ATR14	$2.10 (18.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.86
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

Volumen Correlación

Largo: -0.58 (weak negative)

Corto: 0.74 (moderate)

Signal:(50) Neutral

Candel Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Candel Therapeutics, Inc. Correlación - Moneda/Commodity

-0.32
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

0.71
( moderate )

Candel Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
Ingresos:	$125 000
Beneficio Bruto:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.